牛津衍生公司 Mirae 获得 540 万美元，用于扩展 AI 慢性病护理平台

What You Should Know AI-driven continuous care platform Mirae has officially launched with $5.4M in funding led by Oxford Science Enterprises (OSE). Built directly on computational health research from the University of Oxford’s Computational Health Informatics Lab, co-founded by Dr. David Clifton and CEO Anuj Patel. Targets inflammatory bowel disease (IBD)—a complex autoimmune condition characterized by unpredictable flare-ups, variable treatment responses, and high annual medical expenditure. Uses conversational AI to convert unorganized, everyday patient inputs (symptoms, behavior, medication changes) into structured longitudinal trajectories for clinician copilots. Actively deployed with a leading U.S. health system to ingest real-world patient data streams for ongoing clinical model validation and point-of-care workflow integration. Conversational Patient Ingestion and Oxford AI Modeling The gastroenterology, autoimmune disease management, and digital therapeutics sectors face a major structural challenge: chronic conditions evolve continuously, yet clinical medicine is delivered episodically. Complex autoimmune diseases like Inflammatory Bowel Disease (IBD)—comprising Crohn’s disease and ulcerative colitis—place an immense financial burden on health systems, with chronic conditions projected to cost the U.S. up to $47 trillion over the next 15 years. Despite this high cost, care delivery remains constrained by brief, infrequent office visits. Clinicians are forced to make complex medication decisions and flare evaluations based on limited snapshots and imperfect patient recall. Concurrently, patients navigate daily symptom triggers, medication side effects, and subtle disease progressions without structured decision-support tools, leading to delayed interventions and avoidable inpatient hospitalizations. To eliminate between-visit blindspots and establish a continuous, data-driven system of specialty care, Mirae combines everyday patient-reported inputs with clinical records and peer-reviewed evidence to power an AI copilot for gastroenterologists and specialty clinicians. Mirae’s platform acts as an ambient intelligence and synthesis layer operating between patients and clinical EHRs: Unstructured Conversational Input: Enables patients to log daily behaviors, medication reactions, and symptoms in plain language, using conversational AI to ask targeted follow-up questions and track underlying disease patterns. Structured Trajectory Engine: Converts informal patient narratives into structured clinical data streams, mapping real-time symptom curves against historical lab values and treatment regimens. Point-of-Care Clinician Copilot: Generates a pre-visit longitudinal summary for specialty physicians, distilling months of patient experience into actionable clinical trends before the appointment begins. Oxford Algorithmic Foundation: Built on disease progression modeling research led by co-founder Dr. David Clifton at Oxford, ensuring AI outputs align with peer-reviewed clinical evidence. “Where you live should not dictate the quality of care you receive. A lot of the variability in care and outcomes comes from the fact that clinicians are working without a full view of what has happened between visits,” stated Anuj Patel, co-founder and CEO of Mirae. “When you combine experiential data with clinical data, you begin to understand and model disease more effectively and have a path towards true precision medicine.”